Poznań University of Medical Sciences and Pikralida sp. z o. o. conduct the project cofinanced with the European Funds named Development of an innovative combination drug formulation dedicated for the geriatric patients in pain pharmacotherapy.
POIR.04.01.04-00-0063/20-00 project is conducted as a part of 2014 – 2020 Smart Growth Operational Program, Priority Axis IV Enhancement of the scientific and research potential, subaction 4.1.4.
The aim of this project is to develop a two-component drug for the treatment of pain induced by the spasms of smooth muscles. The two-component formulation is a response to the common in the clinical practice combination of two active substances with different targets. The concept of the formulations with the physical modification leading to the increase in the API solubility and, in consequence, a decrease in dosing and elimination of complicated dosing algorithms is a solid justification for the development of a combination formulation in the pain treatment of geriatric patients.
- Project budget: 3,968,375.00 PLN
- Co-financing of the project from the EU: 3,496,450.00 PLN
- Project timeline: 01.01.2021 – 31.12.2023
The project is co-financed by the European Union under the Smart Growth Operational Program. The program is conducted as a part of 1/4.1.4/2020 – Application Projects competition from the National Center for Research and Development.
Development of an innovative pilot line and its validation under real conditions using synthesis process of a model active pharmaceutical ingredient.
Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.
Development of an innovative combined preparation dedicated for the treatment of hypertension.
Establishment of a R&D Laboratory of Super Generic Drugs.